-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple myeloma (MM) is a blood cancer caused by the proliferation and accumulation of abnormal plasma cells in the bone marrow
Multiple myeloma (MM) is a blood cancer caused by the proliferation and accumulation of abnormal plasma cells in the bone marrow
The study reported here was designed to evaluate the outcomes of a dara-containing regimen in a Canadian real-world setting for relapsed and refractory MM available in the Canadian National Myeloma Research Group Database (CMRG-DB)
Figure 1 : Survival outcomes for DARA-based treatment lines: (A) progression-free survival; (B) overall survival
Figure 1 : Survival outcomes for DARA-based treatment lines: (A) progression-free survival; (B) overall survival
Median PFS and OS were 23.
Table: Daclatumumab-Based Efficacy
Table: Daratumumab-Based Efficacy Table: Daratumumab-Based EfficacyFigure 2: Survival outcomes based on DARA-based regimen types: (A) progression-free survival; (B) overall survival
Figure 2: Survival outcomes based on DARA-based regimen types: (A) progression-free survival; (B) overall survival
The addition of bortezomib, lenalidomide, or pomalidomide to dara improved median PFS and OS, respectively, 8.
Taken together, these retrospective data from the CMRG-DB demonstrate that dara-based combination therapy is effective in managing relapsed and refractory MM and provide a benchmark for expected outcomes in real patients
Original source:
Original source:LeBlanc, R ,Mian, H ,Reece, D ,Masih-Khan, E ,Kardjadj, M ,Jimenez-Zepeda, VH , et al.
LeBlanc, R , Mian, H , Reece, D , Masih-Khan, E , Kardjadj, M , Jimenez-Zepeda, VH , et al.
Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database .
Br J Haematol .
2022 ; 00 : 1 – 10.
https://doi.
org/10.
1111/bjh.
18172.
LeBlanc, R , Mian, H , Reece, D , Masih-Khan, E , Kardjadj, M , Jimenez-Zepeda, VH , et al.
Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database .
Br J Haematol .
2022 ; 00 : 1 – 10.
https://doi.
org/10.
1111/bjh.
18172.
LeBlanc, R Mian, H Reece, D Masih-Khan, E Kardjadj, M Jimenez-Zepeda, VH Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database Br J Haematol 2022 00 1 10
here message
